PharmaMar along with Jazz Pharmaceuticals plc has announced that the International Association for the Study of Lung Cancer (IASLC) has released the abstracts to be presented during the IASLC 2020 World Conference on Lung Cancer, which will be held virtually from January 28th to 31st. One oral presentation and three posters will be presented on ZepzelcaTM (lurbinectedin) during the congress. In the oral presentation, new data on the lurbinectedin combination with irinotecan in relapsed Small Cell Lung Cancer (SCLC) will be presented, under the abstract "Lurbinectedin with irinotecan in relapsed small cell lung cancer.

Results from the expansion stage of a phase I-II trial. This combination of lurbinectedin and irinotecan demonstrated efficacy in SCLC after failure of first-line therapy, including “remarkable activity in patients with resistant disease (CTFI <90 days) and in the 3rd line setting”. Moreover, toxicity was transient and manageable, and consisted mainly of hematological abnormalities, fatigue and diarrhea.

The updated results of this cohort will be presented at the conference. In addition, the Company will present the poster “Semi-mechanistic models of the Time Course of Neutrophils and Platelets in Cancer patients treated with lurbinectedin”, which shows that lurbinectedin dosed at 3.2 mg/m² administered every three weeks can be safely administered without primary prophylaxis. These data have demonstrated that in cancer patients receiving lurbinectedin, neutropenia and thrombocytopenia observed were non-cumulative, reversible, short lasting and clinically manageable.